Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure
- PMID: 495513
- DOI: 10.1016/0002-9149(79)90186-3
Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure
Abstract
Changes in left ventricular performance were evaluated in 14 patients with functional New York Heart Association class III or IV chronic heart failure before and after the addition of oral hydralazine to conventional therapy. With conventional therapy, cardiac output increased from 3.4 +/- 0.8 (mean +/- 1 standard deviation) at rest to 4.7 +/- 1.4 liters/min during exercise. This increase in cardiac output on exercise during conventional therapy was mainly due to an increase in heart rate. After the addition of hydralazine, cardiac output at rest increased to 5.0 +/- 1.4 liters/min. The increase in cardiac output was essentially due to an increase in stroke volume. This enhanced stroke volume after hydralazine therapy was maintained during exercise. Hydralazine therapy did not change either the left ventricular filling pressure at rest or the magnitude of increase in left ventricular filling pressure during exercise. Nevertheless, increased cardiac output and stroke volume with similar changes in left ventricular filling pressure during exercise indicated improved left ventricular performance after hydralazine therapy. After short-term hydralazine therapy, symptom-limited peak exercise work load, duration of exercise and maximal oxygen consumption during exercise did not increase. Clinical follow-up at 2 months after long-term therapy revealed subjective improvement in exercise tolerance in 13 of the 14 patients.
Similar articles
-
Hydralazine therapy in severe chronic heart failure: inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response.J Am Coll Cardiol. 1983 Nov;2(5):887-93. doi: 10.1016/s0735-1097(83)80236-8. J Am Coll Cardiol. 1983. PMID: 6313788
-
Effects of acute and chronic minoxidil administration on rest and exercise hemodynamics and clinical status in patients with severe, chronic heart failure.Am J Cardiol. 1982 Nov;50(5):960-6. doi: 10.1016/0002-9149(82)90402-7. Am J Cardiol. 1982. PMID: 7137047
-
Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction.Circulation. 1980 Apr;61(4):751-8. doi: 10.1161/01.cir.61.4.751. Circulation. 1980. PMID: 7357717
-
Hydralazine in heart failure.Herz. 1983 Aug;8(4):187-98. Herz. 1983. PMID: 6413340 Review.
-
Effectiveness of long-term vasodilator administration in the treatment of chronic left ventricular failure.Prog Cardiovasc Dis. 1982 Jan-Feb;24(4):319-30. doi: 10.1016/0033-0620(82)90009-3. Prog Cardiovasc Dis. 1982. PMID: 7034048 Review. No abstract available.
Cited by
-
Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.Clin Pharmacokinet. 1989 Feb;16(2):86-9. doi: 10.2165/00003088-198916020-00003. Clin Pharmacokinet. 1989. PMID: 2656046 Review.
-
Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.Cardiovasc Drugs Ther. 1989 Jun;3(3):375-96. doi: 10.1007/BF01858109. Cardiovasc Drugs Ther. 1989. PMID: 2487535 Review.
-
The treatment of heart failure. A methodological review of the literature.Drugs. 1986 Dec;32(6):538-68. doi: 10.2165/00003495-198632060-00004. Drugs. 1986. PMID: 3024949 Review.
-
Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.Drugs. 1994;47 Suppl 4:47-57; discussion 57-8. doi: 10.2165/00003495-199400474-00008. Drugs. 1994. PMID: 7523062 Review.
-
Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.Br Heart J. 1981 Apr;45(4):376-84. doi: 10.1136/hrt.45.4.376. Br Heart J. 1981. PMID: 7225252 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources